605 related articles for article (PubMed ID: 33742318)
1. The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk.
Caussy C; Aubin A; Loomba R
Curr Diab Rep; 2021 Mar; 21(5):15. PubMed ID: 33742318
[TBL] [Abstract][Full Text] [Related]
2. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk.
Muzurović E; Mikhailidis DP; Mantzoros C
Metabolism; 2021 Jun; 119():154770. PubMed ID: 33864798
[TBL] [Abstract][Full Text] [Related]
3. Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: A meta-analysis with bias analysis.
Morrison AE; Zaccardi F; Khunti K; Davies MJ
Liver Int; 2019 Mar; 39(3):557-567. PubMed ID: 30358050
[TBL] [Abstract][Full Text] [Related]
4. Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective.
Rhee EJ
Endocrinol Metab (Seoul); 2019 Sep; 34(3):226-233. PubMed ID: 31565874
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission.
Wild SH; Walker JJ; Morling JR; McAllister DA; Colhoun HM; Farran B; McGurnaghan S; McCrimmon R; Read SH; Sattar N; Byrne CD;
Diabetes Care; 2018 Feb; 41(2):341-347. PubMed ID: 29167212
[TBL] [Abstract][Full Text] [Related]
6. Update on cardiovascular risk in nonalcoholic fatty liver disease.
Johnston MP; Patel J; Byrne CD
Curr Opin Cardiol; 2021 Jul; 36(4):478-486. PubMed ID: 34059612
[TBL] [Abstract][Full Text] [Related]
7. Nonalcoholic fatty liver disease - A multisystem disease?
Mikolasevic I; Milic S; Turk Wensveen T; Grgic I; Jakopcic I; Stimac D; Wensveen F; Orlic L
World J Gastroenterol; 2016 Nov; 22(43):9488-9505. PubMed ID: 27920470
[TBL] [Abstract][Full Text] [Related]
8. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.
Dongiovanni P; Paolini E; Corsini A; Sirtori CR; Ruscica M
Eur J Clin Invest; 2021 Jul; 51(7):e13519. PubMed ID: 33583033
[TBL] [Abstract][Full Text] [Related]
9. Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter.
Chiriac S; Stanciu C; Girleanu I; Cojocariu C; Sfarti C; Singeap AM; Cuciureanu T; Huiban L; Muzica CM; Zenovia S; Nastasa R; Trifan A
Can J Gastroenterol Hepatol; 2021; 2021():6696857. PubMed ID: 33505944
[TBL] [Abstract][Full Text] [Related]
10. Management of dyslipidemia as a cardiovascular risk factor in individuals with nonalcoholic fatty liver disease.
Corey KE; Chalasani N
Clin Gastroenterol Hepatol; 2014 Jul; 12(7):1077-84; quiz e59-60. PubMed ID: 23962548
[TBL] [Abstract][Full Text] [Related]
11. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors.
Muzurović E; Peng CC; Belanger MJ; Sanoudou D; Mikhailidis DP; Mantzoros CS
Hypertension; 2022 Jul; 79(7):1319-1326. PubMed ID: 35465684
[TBL] [Abstract][Full Text] [Related]
12. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases.
Adams LA; Anstee QM; Tilg H; Targher G
Gut; 2017 Jun; 66(6):1138-1153. PubMed ID: 28314735
[TBL] [Abstract][Full Text] [Related]
13. Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association.
Lee BW; Lee YH; Park CY; Rhee EJ; Lee WY; Kim NH; Choi KM; Park KG; Choi YK; Cha BS; Lee DH;
Diabetes Metab J; 2020 Jun; 44(3):382-401. PubMed ID: 32431115
[TBL] [Abstract][Full Text] [Related]
14. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
15. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
[TBL] [Abstract][Full Text] [Related]
16. Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases.
Cai J; Zhang XJ; Ji YX; Zhang P; She ZG; Li H
Circ Res; 2020 Feb; 126(5):679-704. PubMed ID: 32105577
[TBL] [Abstract][Full Text] [Related]
17. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms.
Møller S; Kimer N; Kronborg T; Grandt J; Hove JD; Barløse M; Gluud LL
Semin Liver Dis; 2021 Aug; 41(3):235-247. PubMed ID: 33992031
[TBL] [Abstract][Full Text] [Related]
18. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
19. Prevalences of Hypertension, Type 2 Diabetes Mellitus, and Cardiovascular Disease in a Cohort of Puerto Ricans with Non-alcoholic Fatty Liver Disease.
González-Rivera A; Vargas-Figueroa VM; Candal-Rivera E; Torres EA
P R Health Sci J; 2024 Mar; 43(1):18-24. PubMed ID: 38512757
[TBL] [Abstract][Full Text] [Related]
20. Nonalcoholic Fatty Liver Disease (NAFLD) and Cardiovascular Risk: Is Imaging Helpful?
Doumas SA; Tripathi S; Kashikar A; Khuttan A; Kumar A; Singh H; Canakis JP; Ashish K; Dey D; Oppenheim I; Dey AK
Curr Probl Cardiol; 2024 Jan; 49(1 Pt B):102065. PubMed ID: 37652112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
